News
AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.
5hOpinion
Zacks.com on MSNThe Next Leg Up Has Just Begun: Why I'm Expecting A 20% Gain Over The Next 6 MonthsWith the market now full recovered from the tariff-driven selloff, investors should get ready for another double-digit market ...
The loss of Walmart in 2018 and Gap in 2021 were significant blows, as the Walmart credit card program was about 13% of Synchrony’s receivables at the time, and the Gap credit card program was about 5 ...
NervGen Pharma targets a neglected market with significant unmet needs, offering high-risk, high-reward potential if NVG-291 ...
Something for the weekend - why we should all be appalled by Meta’s latest super-intelligence gambit
Meta is in talks to quasi-acquire Scale AI to create a new lab for “super-intelligence.” Although Scale AI pitches itself as ...
Stablecoins are rapidly evolving from a niche vertical in the cryptocurrency ecosystem into a foundational element of the global financial system. A new analysis looks at this burgeoning ecosystem, ...
To a programmer, code can seem a “domain of sorcery” in which strings of characters have power in the real world.
The job title Quant is ubiquitously used. That makes it a dynamic, exciting and dynamic discipline, but one which also can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results